TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Turning Point Therapeutics, Inc.

10628 Science Center Drive
Suite 200
San Diego, CA 92121
United States
858 926 5251

Full Time Employees87

Key Executives

NameTitlePayExercisedYear Born
Dr. Athena Maria CountouriotisPres, CEO & Director897.1kN/A1972
Dr. Jingrong Jean Cui Ph.D.Co-Founder, Consultant & Director641.9kN/A1964
Mr. Brian L. Baker CPA, M.S., MS, CPAVP of Fin. & Admin.316.39kN/A1967
Ms. Yi LarsonExec. VP & CFON/AN/A1980
Dr. Siegfried ReichExec. VP & Chief Scientific OfficerN/AN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Turning Point Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.